Prostate cancer is the most common cancer diagnosed in men. With over 1.4 million cases reported worldwide in 2020, the incidence rates continue to rise with wider availability of screening tests, such as PSA. Each prostate case consists of multiple biopsy core whole slide images, which must be assessed by a pathologist for the presence of tumour and, if present, a Gleason score is reported. This represents a large workload for pathologists who screen multiple cases daily. HALO Prostate AI is designed to work alongside the pathologist to improve efficiency and to add a layer of quality control to ensure diagnostic accuracy.
Developed in close collaboration with Dr Yuri Tolkach and colleagues from the University of Cologne, HALO Prostate AI was trained using over 870,000 training patches obtained from the annotation of digital scans representing the full spectrum of prostate cancer subtypes and Gleason grades, as well as benign tissue. The algorithm achieved high sensitivity (95–100%), specificity (88–98%) and negative predictive value (98–100%) in validation studies performed on 4973 core needle biopsies from three independent cohorts sourced from hospitals in Austria and Germany. Highlighting the unique benefit of HALO Prostate AI screening on diagnostic accuracy and patient care, the algorithm correctly detected tumour in 26 cores within the validation study that were originally reported as tumour negative.
In a separate study, Gleason scores obtained from HALO Prostate AI were compared against scores assigned by pathologists located in 10 globally distributed hospitals. Nine pathologists who participated in the study were board-certified in genitourinary pathology. High concordance was achieved for two separate cohorts with representative average quadratic Kappa scores of 0.8 and 0.7.
"I am very excited about the digital future of pathology," commented Dr Tolkach. "With tools such as HALO Prostate AI, our work can be substantially optimised while controlling for high-quality, reliable and objective diagnostics. HALO Prostate AI showed very high accuracy in the large multi-institutional study for tumour detection and Gleason grading in prostate biopsies. It’s really enjoyable to work back-to-back with such a powerful AI assistant."
Dr Peter Caie, Principal Scientist of AI Collaboration at Indica Labs, added, "This has been a hugely positive collaboration with Dr Tolkach and contributing pathologists from around the world. We set out to build a clinical-grade algorithm that could improve turnaround time and diagnostic accuracy for prostate cancer patients, and I believe that is exactly what we have achieved. We are thrilled to see the first of many AI algorithms from Indica Labs attain CE-IVD marking and to begin to be used in clinical settings to help alleviate the pressure of ever-increasing workloads."
NEWS
Certification for AI-based prostate cancer detection and Gleason grading tool
Indica Labs, a provider of computational pathology software and services, has announced a CE-IVD mark for HALO Prostate AI, a screening tool designed to assist pathologists in identifying and grading prostate cancer in needle biopsies.
FEATURES
Expression of PRAME in melanocytic lesions: significance and evaluation
Immunohistochemistry is a vital tool in the classification of melanocytic skin lesions. Here, Karolina Wojcik and colleagues assess PRAME expression as a new marker in recognising and distinguishing the malignant melanomas from atypical naevi.
IBMS Congress 2022: from microbiology via POCT to virology
Summaries of lectures on the comprehensive Biomedical Science Congress scientific lecture programme are requested from individual speakers. In this second review, Pathology in Practice selects highlights from alphabetically microbiology to virology.
Monocyte distribution width: importance in early detection of sepsis
The International Symposium on Intensive Care and Emergency Medicine featured a live symposium hosted by Beckman Coulter devoted to the role of monocyte distribution width. Here, speakers take part in a question and answer session.
Impressions and reflections of the IBMS Congress 2022 event
The IBMS Congress held in Birmingham in March was a welcome return to face-to-face conference normality. Siobhan Brown from Roche Diagnostics provides an overview of the company’s experiences at the 14th iteration of this important biennial event.
PRODUCTS
LATEST ISSUEs
Featured Supplier
Haier Biomedical was founded in 1998 to focus on design, manufacturing and sales of reliable and durable products for clinicians and life scientists around the world. Using the concept of the Internet of Things (IoT), Haier Biomedical has become a leading provider of comprehensive solutions for many biotechnological challenges.
Haier...
Upcoming Events
analytica 2022
Messe München, Germany
June 21-24, 2022
The Genomic and Microbiology Revolution: In Technology We Trust?
Royal Air Force Museum, Hendon, London
19 July 2022
Arab Lab Live 2022
Dubai International Convention & Exhibition Centre Dubai World Trade Centre - Trade Centre - Trade Centre 2 - Dubai - United Arab Emirates
24 - 26 October 2022
Lab Innovations 2022
Hall 2 NEC, Birmingham
2 & 3 November 2022
MEDICA 2022
Messe Düsseldorf D-40474 Düsseldorf, Stockumer Kirchstraße 61
14 - 17 November 2022
Access the latest issue of Pathology In Practice on your mobile device together with an archive of back issues.
Download the FREE Pathology In Practice app from your device's App store